Publications

5600 Results

A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 (Excision Repair Cross-Complementing 1) for advanced/ metastatic esophageal, gastric or gastroesophageal junction (GEJ) cancer: SWOG S1201

Authors
S Iqbal;S McDonough;H Lenz;D Ilson;B Burtness;CS Nangia;A Barzi;CJ Schneider;J Liu;E Dotan;K Guthrie;H Hochster
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 4009); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
S1201

SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer

Authors
R Kim;S McDonough;A El-Khoueiry;T Bekaii-Saab;SM Stein;V Sahai;GP Keogh;EJ Kim;AD Baron;AB Siegel;A Barzi;K Guthrie;M Javle;H Hochster
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 4016); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussioin
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
S1310

Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)

Authors
ES Kopetz;S McDonough;H Lenz;A Magliocco;C Atreya;L Diaz;C Allegra;K Raghav;VK Morris;S Wang;C Lieu;K Guthrie;H Hochster
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3505); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral presentation
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
S1406

Randomized phase II study of 2nd line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513

Authors
EG Chiorean;S McDonough;PA Philip;E Swisher;M Pishvaian;K Guthrie;A Lowy;H Hochster
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr TPS4147); American Society of Clinical Oncology (ASCO) Annual Meeting(June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
S1513

Patterns of osteoporosis (OP) in survivors of colorectal cancer (CRC) enrolled on SWOG trials

Authors
A Barzi;D Hershman;C Till;H Lenz;H Hochster;W Barlow;J Unger
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 10056); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-9304 (INT-0144), SWOG-9415 (INT-0153) (CALGB-9498) (ECOG-S9415) (NCCTG-S9415), SWOG-9420

Primary tumor location is an independent prognostic maker from CMS and MSI for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

Authors
A Venook;FS Ou;F Innocenti;H Hochster;D Niedzwiecki;R Goldberg;R Mayer;M Bertagnolli;C Blanke;T Zemla;X Qu;O Kabbarah;H Lenz
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3503); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 Alliance)

Authors
F Innocenti;FS Qu;T Zemla;D Niedzwiecki;X Qu;R Tam;SA Mahajan;R Goldberg;RJ Mayer;M Bertagnolli;H Hochster;C Blanke;A Venook;H Lenz;O Kabbarah
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3504); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)

Authors
H Lenz;FS Ou;A Venook;H Hochster;D Niedzwiecki;R Goldberg;R Mayer;M Bertagnolli;C Blanke;T Zemla;X Qu;O Kabbarah;F Innocenti
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 3511); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral presentation
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 versus 6 months) for patients with stage III colon cancer: The IDEA(International Duration Evaluation of Adjuvant chemotherapy) collaboration

Authors
Q Shi;A Sobrero;A Shields;T Yoshino;J Taieb;I Souglakos;R Kerr;R Labianca;J Meyerhardt;F Bonnetain;T Watanabe;I Mpoukovinas;L Renfro;A Grothey;D Niedzwiecki;V Torri;T Andre;D Sargent
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr LBA1); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral, plenary
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

American cancer society (ACS) nutrition and physical activity guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance)

Authors
E Van Blarigan;C Fuchs;D Niedzwiecki;X Ye;S Zhang;M Song;L Saltz;RJ Mayer;RB Mowat;R Whittom;A Hantel;A Benson;D Atienza;M Messino;H Kindler;A Venook;S Ogino;W Willett;EL Giovannucci;J Meyerhardt
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 10006); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral presentation
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
C89803